Pathology and biology of peripheral T-cell lymphomas

Histopathology

Volumn 58, Issue 1, 2011, Pages 49-68

  De Leval, Laurence ^a   Gaulard, Philippe ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Biology; Cellular origin; Diagnosis; Pathobiology; Peripheral T cell lymphoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD103 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CLATHRIN HEAVY CHAIN; EPITHELIAL MEMBRANE ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LEUKOCYTE ANTIGEN; MOESIN; NUCLEOPHOSMIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; T LYMPHOCYTE RECEPTOR; TROPOMYOSIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AGGRESSIVE NK CELL LEUKEMIA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; CLINICAL FEATURE; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EPSTEIN BARR VIRUS; FOLLICULAR DENDRITIC CELL; GAMMA DELTA T CELL LYMPHOMA; GAMMA DELTA T LYMPHOCYTE; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; HYDROA VACCINIFORME; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOMATOID PAPULOSIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; NK T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SEZARY SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, EXTRANODAL NK-T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; T-LYMPHOCYTES;

EID: 78851470560     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03704.x     Document Type: Review

References (131)

1. Rudiger T, Weisenburger DD, Anderson JR et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann. Oncol. 2002; 13; 140-149.
2. Swerdlow S, Campo E, Harris N et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
3. Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101; 3407-3412.
4. de Leval L, Rickman DS, Thielen C et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109; 4952-4963.
5. Tripodo C, Iannitto E, Florena AM et al. Gamma-delta T-cell lymphomas. Nat. Rev. 2009; 6; 707-717.
6. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 2008; 26; 4124-4130.
7. Martinez-Delgado B, Melendez B, Cuadros M et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin. Cancer Res. 2004; 10; 4971-4982.
8. Martinez-Delgado B, Cuadros M, Honrado E et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19; 2254-2263.
9. Ballester B, Ramuz O, Gisselbrecht C et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25; 1560-1570.
10. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 2007; 117; 823-834.
11. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007; 67; 10703-10710.
12. Cuadros M, Dave SS, Jaffe ES et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J. Clin. Oncol. 2007; 25; 3321-3329.
13. Iqbal J, Kucuk C, Deleeuw RJ et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23; 1139-1151.
14. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin. Hematol. 2003; 40; 175-184.
15. Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2006; 317-322.
16. Bossard C, Belhadj K, Reyes F et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2006; 31; 2183-2189.
17. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54; 182-190.
18. Boulland ML, Meignin V, Leroy-Viard K et al. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am. J. Pathol. 1998; 153; 1229-1237.
19. Teruya-Feldstein J, Jaffe ES, Burd PR et al. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997; 90; 4099-4105.
20. Nakashima Y, Tagawa H, Suzuki R et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosom. Cancer 2005; 44; 247-255.
21. Taborelli M, Tibiletti MG, Martin V, Pozzi B, Bertoni F, Capella C. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet. Cytogenet. 2006; 165; 106-113.
22. Huang Y, de Reynies A, de Leval L et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115; 1226-1237.
23. Coppo P, Gouilleux-Gruart V, Huang Y et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 2009; 23; 1667-1678.
24. Quintanilla-Martinez L, Kremer M, Keller G et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am. J. Pathol. 2001; 159; 2095-2105.
25. Takakuwa T, Dong Z, Nakatsuka S et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 2002; 21; 4702-4705.
26. Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM. CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood 2003; 102; 2623-2631.
27. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113; 3931-3937.
28. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 2004; 101; 1404-1413.
29. Groh V, Fabbi M, Hochstenbach F, Maziarz RT, Strominger JL. Double-negative (CD4-CD8-) lymphocytes bearing T-cell receptor alpha and beta chains in normal human skin. Proc. Natl Acad. Sci. USA 1989; 86; 5059-5063.
30. Farcet JP, Gaulard P, Marolleau JP et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990; 75; 2213-2219.
31. Suarez F, Wlodarska I, Rigal-Huguet F et al. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am. J. Surg. Pathol. 2000; 24; 1027-1032.
32. Macon WR, Levy NB, Kurtin PJ et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am. J. Surg. Pathol. 2001; 25; 285-296.
33. Belhadj K, Reyes F, Farcet J-P et al. Hepatosplenic {gamma}{delta} T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 cases. Blood 2003; 2003-2005-1675.
34. Cooke C, Greiner T, Raffeld M, Kingma D, Stetler-Stevenson M, Jaffe E. gd T-cell lymphoma: a distinct clinicopathologic entity. Mod. Pathol. 1994; 7; 106A.
35. Baseggio L, Berger F, Monneret G, Magaud JP, Salles G, Felman P. The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell. Haematologica 2006; 91; 1717-1719.
36. Wlodarska I, Martin-Garcia N, Achten R et al. Fluorescence insitu hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosom. Cancer 2002; 33; 243-251.
37. Miyazaki K, Yamaguchi M, Imai H et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 2009; 113; 1071-1074.
38. Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102; 4261-4269.
39. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 2007; 13; 1024-1030.
40. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008; 57; 1639-1641.
41. Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111; 838-845.
42. Toro JR, Beaty M, Sorbara L et al. gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch. Dermatol. 2000; 136; 1024-1032.
43. Arnulf B, Copie-Bergman C, Delfau-Larue M-H et al. Nonhepatosplenic gd T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998; 91; 1723-1731.
44. Wohrer S, Chott A, Drach J et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann. Oncol. 2004; 15; 1680-1683.
45. Ferreri AJ, Zinzani PL, Govi S, Pileri SA. Enteropathy-associated T-cell lymphoma. Crit. Rev. Oncol. Hematol. 2010; Jul 22. [Epub ahead of print].
46. Howell WM, Leung ST, Jones DB et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum. Immunol. 1995; 43; 29-37.
47. van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ. Enteropathy associated T-cell lymphoma and its precursor lesions. Best. Pract. Res. Clin. Gastroenterol. 2010; 24; 43-56.
48. Ashton-Key M, Diss TC, Pan L, Du MQ, Isaacson PG. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am. J. Pathol. 1997; 151; 493-498.
49. Cellier C, Delabesse E, Helmer C et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356; 203-208.
50. Isaacson PG. Relation between cryptic intestinal lymphoma and refractory sprue. Lancet 2000; 356; 178-179.
51. Cellier C, Patey N, Mauvieux L et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998; 114; 471-481.
52. Verbeek WH, Goerres MS, von Blomberg BM et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin. Immunol. 2008; 126; 48-56.
53. Mention JJ, Ben Ahmed M, Begue B et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003; 125; 730-745.
54. Malamut G, El Machhour R, Montcuquet N et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J. Clin. Invest. 2010; 120; 2131-2143.
55. Zettl A, Ott G, Makulik A et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am. J. Pathol. 2002; 161; 1635-1645.
56. Verkarre V, Romana SP, Cellier C et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003; 125; 40-46.
57. Deleeuw RJ, Zettl A, Klinker E et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007; 132; 1902-1911.
58. Chott A, Haedicke W, Mosberger I et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am. J. Pathol. 1998; 153; 1483-1490.
59. Mourad N, Mounier N, Briere J et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111; 4463-4470.
60. Ree HJ, Kadin ME, Kikuchi M et al. Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. Am. J. Surg. Pathol. 1998; 22; 643-655.
61. Attygalle A, Al-Jehani R, Diss TC et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002; 99; 627-633.
62. Attygalle AD, Kyriakou C, Dupuis J et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am. J. Surg. Pathol. 2007; 31; 1077-1088.
63. Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod. Pathol. 2009; 22; 753-761.
64. Lome-Maldonado C, Canioni D, Hermine O et al. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL? Leukemia 2002; 16; 2134-2141.
65. Bruggemann M, White H, Gaulard P et al. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies. Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 2007; 21; 215-221.
66. Brauninger A, Spieker T, Willenbrock K et al. Survival and clonal expansion of mutating 'forbidden' (immunoglobulin receptor-deficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T-cell lymphoma. J. Exp. Med. 2001; 194; 927-940.
67. Zettl A, Lee SS, Rudiger T et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am. J. Clin. Pathol. 2002; 117; 368-379.
68. Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br. J. Haematol. 2007; 138; 733-739.
69. Patsouris E, Noel H, Lennert K. Angioimmunoblastic lymphadenopathy - type of T-cell lymphoma with a high content of epithelioid cells. Am. J. Surg. Pathol. 1989; 13; 262-275.
70. Willenbrock K, Roers A, Seidl C, Wacker HH, Kuppers R, Hansmann ML. Analysis of T-cell subpopulations in T-cell non-Hodgkin's lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia type by single target gene amplification of T cell receptor-beta gene rearrangements. Am. J. Pathol. 2001; 158; 1851-1857.
71. Lee SS, Rudiger T, Odenwald T, Roth S, Starostik P, Muller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int. J. Cancer 2003; 103; 12-20.
72. Stacchini A, Demurtas A, Aliberti S et al. The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am. J. Clin. Pathol. 2007; 128; 854-864.
73. Karube K, Aoki R, Nomura Y et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol. Int. 2008; 58; 89-97.
74. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 2007; 50; 498-508.
75. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat. Rev. Immunol. 2005; 5; 853-865.
76. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 2005; 106; 1501-1502.
77. Dupuis J, Boye K, Martin N et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am. J. Surg. Pathol. 2006; 30; 490-494.
78. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 2006; 30; 802-810.
79. Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 2007; 92; 1059-1066.
80. Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood 2006; 108; 1110-1111.
81. Xerri L, Chetaille B, Seriari N et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum. Pathol. 2008; 39; 1050-1058.
82. Yu H, Shahsafaei A, Dorfman DM. Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am. J. Clin. Pathol. 2009; 131; 33-41.
83. Marafioti T, Paterson JC, Ballabio E et al. The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica 2010; 95; 432-439.
84. Ree HJ, Kadin ME, Kikuchi M, Ko YH, Suzumiya J, Go JH. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma. Hum. Pathol. 1999; 30; 403-411.
85. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum. Pathol. 2005; 36; 784-791.
86. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br. J. Haematol. 2010; 148; 673-689.
87. de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P. Molecular classification of T-cell lymphomas. Crit. Rev. Oncol. Hematol. 2009; 72; 125-143.
88. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br. J. Haematol. 2003; 121; 681-691.
89. Leich E, Haralambieva E, Zettl A et al. Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. J. Pathol. 2007; 213; 99-105.
90. Pulford K, Lamant L, Espinos E et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell. Mol. Life Sci. 2004; 61; 2939-2953.
91. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110; 2259-2267.
92. Stein H, Foss HD, Durkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96; 3681-3695.
93. Bonzheim I, Geissinger E, Roth S et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004; 104; 3358-3360.
94. Ambrogio C, Martinengo C, Voena C et al. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009; 69; 8611-8619.
95. Geissinger E, Sadler P, Roth S et al. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica 2010; 95; 1697-1704.
96. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 2008; 8; 11-23.
97. Piva R, Agnelli L, Pellegrino E et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J. Clin. Oncol. 2010; 28; 1583-1590.
98. Piva R, Pellegrino E, Mattioli M et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J. Clin. Invest. 2006; 116; 3171-3182.
99. Lamant L, de Reynies A, Duplantier MM et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109; 2156-2164.
100. Trumper L, Pfreundschuh M, Bonin FV, Daus H. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. Br. J. Haematol. 1998; 103; 1138-1144.
101. Maes B, Vanhentenrijk V, Wlodarska I et al. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am. J. Pathol. 2001; 158; 2185-2193.
102. Salaverria I, Bea S, Lopez-Guillermo A et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br. J. Haematol. 2008; 140; 516-526.
103. Lamant L, Pileri S, Sabattini E, Brugieres L, Jaffe ES, Delsol G. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica 2010; 95; 449-455.
104. Savage KJ, Harris NL, Vose JM et al. ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111; 5496-5504.
105. Feldman AL, Law ME, Inwards DJ, Dogan A, McClure RF, Macon WR. PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. Mod. Pathol. 2010; 23; 593-602.
106. Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cel lymphoproliferative disorder. Mod. Pathol. 2008; 21; 455-463.
107. Li S, Lee AK. Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int. J. Clin. Exp. Pathol. 2009; 3; 117-127.
108. van der Veldt AA, Kleijn SA, Nanayakkara PW. Silicone breast implants and anaplastic large T-cell lymphoma. JAMA 2009; 301; 1227.
109. Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica 2010; 95; 1977-1979.
110. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92; 76-82.
111. Quintanilla-Martinez L, Fend F, Moguel LR et al. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am. J. Surg. Pathol. 1999; 23; 1233-1240.
112. Dupuis J, Emile JF, Mounier N et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006; 108; 4163-4169.
113. Geissinger E, Odenwald T, Lee SS et al. Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells. Virchows Arch. 2004; 445; 334-343.
114. Patsouris E, Engelhard M, Zwingers T, Lennert K. Lymphoepithelioid cell lymphoma (Lennert's lymphoma): clinical features derived from analysis of 108 cases. Br. J. Haematol. 1993; 84; 346-348.
115. de Leval L, Savilo E, Longtine J, Ferry JA, Harris NL. Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+ phenotype. Am. J. Surg. Pathol. 2001; 25; 395-400.
116. Rudiger T, Ichinohasama R, Ott MM et al. Peripheral T-cell lymphoma with distinct perifollicular growth pattern: a distinct subtype of T-cell lymphoma? Am. J. Surg. Pathol. 2000; 24; 117-122.
117. Ikonomou IM, Tierens A, Troen G et al. Peripheral T-cell lymphoma with involvement of the expanded mantle zone. Virchows Arch. 2006; 449; 78-87.
118. Huang Y, Moreau A, Dupuis J et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am. J. Surg. Pathol. 2009; 33; 682-690.
119. Bacon CM, Paterson JC, Liu H et al. Peripheral T-cell lymphoma with a follicular growth pattern: derivation from follicular helper T cells and relationship to angioimmunoblastic T-cell lymphoma. Br. J. Haematol. 2008; 143; 439-441.
120. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006; 20; 313-318.
121. Feldman AL, Sun DX, Law ME et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008; 22; 1139-1143.
122. Wilcox RA, Sun DX, Novak A, Dogan A, Ansell SM, Feldman AL. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia 2010; 24; 229-232.
123. Rudiger T, Geissinger E, Muller-Hermelink HK. 'Normal counterparts' of nodal peripheral T-cell lymphoma. Hematol. Oncol. 2006; 24; 175-180.
124. Went P, Agostinelli C, Gallamini A et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J. Clin. Oncol. 2006; 24; 2472-2479.
125. de Leval L, Rickman D, Thielen C et al. The gene expression profile of nodal T-cell lymphomas identifies a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T cells (TFH), and between CD30+ peripheral T-cell lymphoma and ALK-negative anaplastic large cell lymphoma (ALCL). Blood 2006; 108; 289.
126. Iqbal J, Weisenburger DD, Greiner TC et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115; 1026-1036.
127. Asano N, Suzuki R, Kagami Y et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am. J. Surg. Pathol. 2005; 29; 1284-1293.
128. Zettl A, Rudiger T, Konrad MA et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am. J. Pathol. 2004; 164; 1837-1848.
129. Thorns C, Bastian B, Pinkel D et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom. Cancer 2007; 46; 37-44.
130. Nelson M, Horsman DE, Weisenburger DD et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br. J. Haematol. 2008; 141; 461-469.
131. Piccaluga PP, Agostinelli C, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol. 2005; 6; 440.